Published in Genomics on May 22, 2006
Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer | NCT00403221
Spatio-temporal transcriptome of the human brain. Nature (2011) 9.19
Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors. Neoplasia (2007) 1.03
GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res (2011) 0.98
Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential. Yonsei Med J (2010) 0.92
Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells. Front Oncol (2013) 0.91
Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. Clin Med Insights Oncol (2015) 0.90
The role of cysteine-rich secretory proteins in male fertility. Asian J Androl (2010) 0.90
Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol (2012) 0.86
Structural studies of human glioma pathogenesis-related protein 1. Acta Crystallogr D Biol Crystallogr (2011) 0.86
MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol (2010) 0.81
SB225002 Induces Cell Death and Cell Cycle Arrest in Acute Lymphoblastic Leukemia Cells through the Activation of GLIPR1. PLoS One (2015) 0.78
GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin. PLoS One (2017) 0.75
Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol (2003) 2.20
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res (2007) 1.94
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res (2002) 1.89
Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res (2004) 1.77
Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol (2007) 1.66
Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys (2006) 1.50
Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res (2008) 1.37
mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol (2002) 1.27
RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res (2004) 1.25
Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res (2008) 1.24
Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res (2003) 1.22
Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res (2006) 1.17
Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol (2003) 1.16
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res (2006) 1.16
Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther (2007) 1.12
Using caveolin-1 knockout mouse to study impaired detrusor contractility and disrupted muscarinic activity in the aging bladder. Urology (2007) 1.09
Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther (2003) 1.08
Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer (2005) 1.08
Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol (2007) 1.06
Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther (2009) 1.04
Bystin in perineural invasion of prostate cancer. Prostate (2006) 1.01
Loss of caveolin-1 expression is associated with disruption of muscarinic cholinergic activities in the urinary bladder. Neurochem Int (2004) 1.01
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res (2011) 1.00
Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol (2007) 1.00
Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res (2009) 0.99
Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res (2009) 0.99
GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res (2011) 0.98
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther (2006) 0.98
The role of caveolin-1 in androgen insensitive prostate cancer. J Urol (2002) 0.97
E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther (2004) 0.94
Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer (2003) 0.94
Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther (2002) 0.92
Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res (2013) 0.91
Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am J Surg (2008) 0.91
Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res (2003) 0.91
Hox transcription factor ultrabithorax Ib physically and genetically interacts with disconnected interacting protein 1, a double-stranded RNA-binding protein. J Biol Chem (2004) 0.90
Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett (2008) 0.90
GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer. Cancer Cell (2013) 0.90
Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res (2010) 0.88
Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res (2003) 0.88
Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res (2011) 0.88
CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther (2006) 0.88
Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol (2012) 0.86
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res (2008) 0.86
Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models. Cancer Biol Ther (2012) 0.86
Transcription activation by ultrabithorax Ib protein requires a predicted alpha-helical region. Biochemistry (2002) 0.84
Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer. Int J Cancer (2013) 0.84
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys (2004) 0.83
Castration-induced changes in mouse epididymal white adipose tissue. Mol Cell Endocrinol (2011) 0.83
The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol (2011) 0.83
Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate (2010) 0.82
MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol (2010) 0.81
Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther (2004) 0.81
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist (2002) 0.80
Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Mol Carcinog (2003) 0.80
Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int J Cancer (2008) 0.80
Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. Hybridoma (Larchmt) (2012) 0.79
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat (2006) 0.78
Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res (2004) 0.77
Therapeutic targets for metastatic prostate cancer. Curr Drug Targets (2003) 0.77
Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Hum Gene Ther (2003) 0.77
Gene therapy for prostate cancer. Expert Rev Anticancer Ther (2002) 0.76